Literature DB >> 35865361

Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients.

Dorothy L Butler1, Luisa Imberti2, Virginia Quaresima2, Chiara Fiorini2, Jeffrey C Gildersleeve1.   

Abstract

Our immune system is critical for preventing and treating SARS-CoV-2 infections, but aberrant immune responses can have deleterious effects. While antibodies to glycans could recognize the virus and influence the clinical outcome, little is known about their roles. Using a carbohydrate antigen microarray, we profiled serum antibodies in healthy control subjects and COVID-19 patients from two separate cohorts. COVID-19 patients had numerous autoantibodies to self-glycans, including antiganglioside antibodies that can cause neurological disorders. Additionally, nearly all antiglycan IgM signals were lower in COVID-19 patients, indicating a global dysregulation of this class of antibodies. Autoantibodies to certain N-linked glycans correlated with more severe disease, as did low levels of antibodies to the Forssman antigen and ovalbumin. Collectively, this study indicates that expanded testing for antiglycan antibodies could be beneficial for clinical analysis of COVID-19 patients and illustrates the importance of including host and viral carbohydrate antigens when studying immune responses to viruses. Published by Oxford University Press on behalf of the National Academy of Sciences 2021.

Entities:  

Year:  2022        PMID: 35865361      PMCID: PMC9291223          DOI: 10.1093/pnasnexus/pgac062

Source DB:  PubMed          Journal:  PNAS Nexus        ISSN: 2752-6542


  75 in total

1.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.

Authors:  Michael J Joyner; R Scott Wright; DeLisa Fairweather; Jonathon W Senefeld; Katelyn A Bruno; Stephen A Klassen; Rickey E Carter; Allan M Klompas; Chad C Wiggins; John Ra Shepherd; Robert F Rea; Emily R Whelan; Andrew J Clayburn; Matthew R Spiegel; Patrick W Johnson; Elizabeth R Lesser; Sarah E Baker; Kathryn F Larson; Juan G Ripoll; Kylie J Andersen; David O Hodge; Katie L Kunze; Matthew R Buras; Matthew Np Vogt; Vitaly Herasevich; Joshua J Dennis; Riley J Regimbal; Philippe R Bauer; Janis E Blair; Camille M van Buskirk; Jeffrey L Winters; James R Stubbs; Nigel S Paneth; Nicole C Verdun; Peter Marks; Arturo Casadevall
Journal:  J Clin Invest       Date:  2020-06-11       Impact factor: 14.808

2.  Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease 2019.

Authors:  Fei Xiang; Xiaorong Wang; Xinliang He; Zhenghong Peng; Bohan Yang; Jianchu Zhang; Qiong Zhou; Hong Ye; Yanling Ma; Hui Li; Xiaoshan Wei; Pengcheng Cai; Wan-Li Ma
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

3.  The Glycan Array Platform as a Tool to Identify Carbohydrate Antigens.

Authors:  Li Xia; Jeffrey C Gildersleeve
Journal:  Methods Mol Biol       Date:  2015

4.  An inflammatory cytokine signature predicts COVID-19 severity and survival.

Authors:  Diane Marie Del Valle; Seunghee Kim-Schulze; Hsin-Hui Huang; Noam D Beckmann; Sharon Nirenberg; Bo Wang; Yonit Lavin; Talia H Swartz; Deepu Madduri; Aryeh Stock; Thomas U Marron; Hui Xie; Manishkumar Patel; Kevin Tuballes; Oliver Van Oekelen; Adeeb Rahman; Patricia Kovatch; Judith A Aberg; Eric Schadt; Sundar Jagannath; Madhu Mazumdar; Alexander W Charney; Adolfo Firpo-Betancourt; Damodara Rao Mendu; Jeffrey Jhang; David Reich; Keith Sigel; Carlos Cordon-Cardo; Marc Feldmann; Samir Parekh; Miriam Merad; Sacha Gnjatic
Journal:  Nat Med       Date:  2020-08-24       Impact factor: 53.440

5.  Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.

Authors:  Christopher T Campbell; James L Gulley; Oyindasola Oyelaran; James W Hodge; Jeffrey Schlom; Jeffrey C Gildersleeve
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

6.  Competition between serum IgG, IgM, and IgA anti-glycan antibodies.

Authors:  Saddam M Muthana; Li Xia; Christopher T Campbell; Yalong Zhang; Jeffrey C Gildersleeve
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

7.  An immune-based biomarker signature is associated with mortality in COVID-19 patients.

Authors:  Michael S Abers; Ottavia M Delmonte; Emily E Ricotta; Jonathan Fintzi; Danielle L Fink; Adriana A Almeida de Jesus; Kol A Zarember; Sara Alehashemi; Vasileios Oikonomou; Jigar V Desai; Scott W Canna; Bita Shakoory; Kerry Dobbs; Luisa Imberti; Alessandra Sottini; Eugenia Quiros-Roldan; Francesco Castelli; Camillo Rossi; Duilio Brugnoni; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio'; Paolo Bonfanti; Riccardo Castagnoli; Daniela Montagna; Amelia Licari; Gian Luigi Marseglia; Emily F Gliniewicz; Elana Shaw; Dana E Kahle; Andre T Rastegar; Michael Stack; Katherine Myint-Hpu; Susan L Levinson; Mark J DiNubile; Daniel W Chertow; Peter D Burbelo; Jeffrey I Cohen; Katherine R Calvo; John S Tsang; Helen C Su; John I Gallin; Douglas B Kuhns; Raphaela Goldbach-Mansky; Michail S Lionakis; Luigi D Notarangelo
Journal:  JCI Insight       Date:  2021-01-11

8.  Post-COVID-19 chronic symptoms: a postinfectious entity?

Authors:  Benjamin Davido; Sophie Seang; Roland Tubiana; Pierre de Truchis
Journal:  Clin Microbiol Infect       Date:  2020-07-23       Impact factor: 13.310

Review 9.  Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.

Authors:  Vibhuti Kumar Shah; Priyanka Firmal; Aftab Alam; Dipyaman Ganguly; Samit Chattopadhyay
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

10.  Site-specific N-glycosylation Characterization of Recombinant SARS-CoV-2 Spike Proteins.

Authors:  Yong Zhang; Wanjun Zhao; Yonghong Mao; Yaohui Chen; Shisheng Wang; Yi Zhong; Tao Su; Meng Gong; Dan Du; Xiaofeng Lu; Jingqiu Cheng; Hao Yang
Journal:  Mol Cell Proteomics       Date:  2021-02-11       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.